“We are pleased to have been selected to continue as a participating provider with the potential for a broader regional reach serving one of the top health insurers in the United States”, said Barry Weiner, President of Enzo Biochem, Inc. “For more than two decades, Enzo Labs has prided itself on the quality of our laboratory work and service, which this selection by United Healthcare underscores. We are excited as well to be able to provide the physicians in our service area with an additional choice for their medical testing needs. Three months ago we were similarly selected by Aetna Health for its laboratory needs, and now, with the new United Healthcare agreement, we believe we have substantially increased our position as a regional lab.”
Enzo Clinical Labs is a leading regional laboratory serving the greater New York/New Jersey area, which covers more than 20 million individuals. The laboratory offers a full menu of state-of-the-art diagnostic procedures in areas such as chemistry, microbiology, hematology, blood banking as well as pathology and genetic testing. Enzo Clinical Labs is currently undergoing an expansion in the number and complexity of tests performed in-house. Our main location in Farmingdale, NY has the capacity to support the expanded testing and the impact from the new contract. Enzo Labs maintains a network of 19 patient service centers, a satellite laboratory in New York City, and a full-service phlebotomy department.
About Enzo
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company’s proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company’s therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn’s Disease. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news release may be considered ”forward‑looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward‑looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
###
Contact:
For: Enzo Biochem, Inc.Steve Anreder, 212-532-3232 Or Ed Lewis, CEOcast, Inc., 212-732-4300